JP3566719B2 - 外来性刺激に対する細胞性応答の調整 - Google Patents

外来性刺激に対する細胞性応答の調整 Download PDF

Info

Publication number
JP3566719B2
JP3566719B2 JP50048393A JP50048393A JP3566719B2 JP 3566719 B2 JP3566719 B2 JP 3566719B2 JP 50048393 A JP50048393 A JP 50048393A JP 50048393 A JP50048393 A JP 50048393A JP 3566719 B2 JP3566719 B2 JP 3566719B2
Authority
JP
Japan
Prior art keywords
cells
pentoxifylline
dag
ptx
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50048393A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07500085A (ja
Inventor
ビアンコ，ジェームズ・エイ
バーステイン，スチュアート・エル
シンガー，ジャック・ダブリュー
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JPH07500085A publication Critical patent/JPH07500085A/ja
Application granted granted Critical
Publication of JP3566719B2 publication Critical patent/JP3566719B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP50048393A 1991-05-24 1992-05-22 外来性刺激に対する細胞性応答の調整 Expired - Fee Related JP3566719B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US732,227 1985-05-08
US70499291A 1991-05-24 1991-05-24
US704,992 1991-05-24
US73222791A 1991-07-16 1991-07-16
PCT/US1992/004349 WO1992021344A2 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Publications (2)

Publication Number Publication Date
JPH07500085A JPH07500085A (ja) 1995-01-05
JP3566719B2 true JP3566719B2 (ja) 2004-09-15

Family

ID=27107424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50048393A Expired - Fee Related JP3566719B2 (ja) 1991-05-24 1992-05-22 外来性刺激に対する細胞性応答の調整

Country Status (7)

Country Link
EP (2) EP1214938A3 (OSRAM)
JP (1) JP3566719B2 (OSRAM)
AU (1) AU664189B2 (OSRAM)
CA (1) CA2109796C (OSRAM)
IE (1) IE921683A1 (OSRAM)
IL (1) IL101982A (OSRAM)
WO (1) WO1992021344A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
ATE230990T1 (de) * 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
US5580874A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
EP0728003A1 (en) 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
EP0708645A1 (en) * 1994-03-08 1996-05-01 Cell Therapeutics, Inc. Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
ATE220549T1 (de) * 1994-12-29 2002-08-15 Univ California Verbindungen zur hemmung der ceramid vermittelten signalübertragung
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
CA2335595A1 (en) * 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
WO2009096616A1 (en) * 2008-01-31 2009-08-06 Korea Institute Of Science And Technology Composition for inhibiting the activity of inositol 1,4,5-triphosphate receptor subtype iii
WO2009096615A1 (en) * 2008-01-31 2009-08-06 Korea Institute Of Science And Technology Composition for preventing or treating brain cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
IL100533A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine for VIH treatment and disease states
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
IL100194A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
ES2093138T3 (es) * 1991-05-23 1996-12-16 Hoechst Ag El empleo de 1-(5-oxohexil)-3-metil-7-n-propil-xantina en cirugia vascular.

Also Published As

Publication number Publication date
EP0573617A1 (en) 1993-12-15
EP1214938A3 (en) 2003-08-06
AU2247592A (en) 1993-01-08
JPH07500085A (ja) 1995-01-05
CA2109796C (en) 2004-04-27
CA2109796A1 (en) 1992-12-10
IL101982A (en) 2000-02-29
IL101982A0 (en) 1992-12-30
WO1992021344A3 (en) 1993-12-09
AU664189B2 (en) 1995-11-09
EP1214938A2 (en) 2002-06-19
WO1992021344A2 (en) 1992-12-10
IE921683A1 (en) 1992-12-02
EP0573617A4 (OSRAM) 1994-02-09

Similar Documents

Publication Publication Date Title
US5585380A (en) Modulation of cellular response to external stimuli
JP3566719B2 (ja) 外来性刺激に対する細胞性応答の調整
JP2753395B2 (ja) 鏡像異性体ヒドロキシル化キサンチン化合物
Allison et al. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
Thornton et al. Moderate alcohol intake reduces bile cholesterol saturation and raises HDL cholesterol
Mehling et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells
US20070173514A1 (en) Methods for suppressing an immune response or treating a proliferative disorder
Jung et al. Does the nature of residual immune function explain the differential risk of non‐melanoma skin cancer development in immunosuppressed organ transplant recipients?
KR20200105731A (ko) 포르볼 에스테르의 조성물
US5340813A (en) Substituted aminoalkyl xanthine compounds
Southam et al. Serum properdin levels and cancer cell homografts in man.
US5440041A (en) Acetal or ketal substituted xanthine compounds
Ulleryd et al. Stimulation of alpha 7 nicotinic acetylcholine receptor (α7nAChR) inhibits atherosclerosis via immunomodulatory effects on myeloid cells
Yeghiazarians et al. IL-15: a novel prosurvival signaling pathway in cardiomyocytes
Hochhuth et al. Effects of antineoplastic phospholipids on parameters of cell differentiation in U937 cells
KR102433644B1 (ko) 체세포로부터 췌장 베타 세포를 직접 분화시키는 방법 및 분화 조성물
US20080176820A1 (en) Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro
JP2005187472A (ja) 抗ｔｎｆ治療と組み合わせた体外フォトフェレーシス
Asano et al. Inhibition of murine chronic graft-versus-host disease by the chloroform extract of Tripterygium wilfordii Hook f
US5795897A (en) Oxohexyl methylxanthine compounds
KR101385488B1 (ko) Src 키나제 억제제에 의한 골용해성 병변의 억제
JP2009521459A (ja) 肝機能障害治療において肝前駆細胞を用いる方法
Stehbens Localization of spontaneous lipid deposition in the cerebral arteries of sheep
CN120960228A (zh) 他泽司他在制备防治心脏移植慢性排斥反应药物中的应用
Wu et al. Prostaglandin E2 Ameliorates Collagen-Induced Arthritis by Enhancing IL-10+ B Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040611

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090618

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100618

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100618

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110618

Year of fee payment: 7

LAPS Cancellation because of no payment of annual fees